Biogen INC

Biogen Inc. announced robust second quarter 2026 financial results, with total revenue reaching $2.7 billion, a 3% year-over-year increase, driven by significant growth in its 'Growth Portfolio'.

Biogen Inc. anticipates significant acquired R&D expenses in Q2 and Q3 2026, impacting EPS.

Biogen Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of ten directors and the ratification of its independent auditor.

Biogen Inc. amends its prior Form 8-K filing regarding the acquisition of Apellis Pharmaceuticals, Inc., stating that financial statements are not required as the acquisition was not significant.

Biogen Inc. has successfully acquired Apellis Pharmaceuticals, Inc., adding two key commercial products and strengthening its position in nephrology and complement-driven diseases.

Biogen announced robust first quarter 2026 financial results, with total revenue reaching $2.5 billion and GAAP diluted EPS surging 31% year-over-year, driven by strong performance in its growth products and pipeline advancements.

Biogen Inc. announced its Q2 2026 financial results, highlighting revenue growth driven by rare disease and specialized immunology products, alongside increased R&D and SG&A expenses due to strategic acquisitions and product launches.

Biogen Inc. reported a 1.9% increase in total revenue to $2.48 billion and a 31.1% rise in diluted EPS to $2.15 for the first quarter of 2026.

Biogen Inc. reported a 2.8% increase in total revenue for Q3 2025, driven by strong performance in rare disease products and LEQEMBI, while reducing R&D expenses.

Biogen's second quarter 2025 saw a 7.3% increase in total revenue driven by strong Alzheimer's collaboration and contract manufacturing, despite a 1.1% decline in net product revenue primarily from its Multiple Sclerosis portfolio.

Biogen's Q1 2025 results show a revenue increase driven by new product launches, but a decrease in earnings due to higher expenses and restructuring initiatives.

Biogen's Q3 2024 results show a revenue decrease, driven by declines in MS product sales, partially offset by growth in rare disease revenue and strategic acquisitions.

Biogen reports 2.2% revenue growth in 2025 driven by new rare disease and neuropsychiatry launches, despite continued decline in MS product sales and increased R&D investments.

Biogen's 2024 10-K filing highlights strategic shifts, pipeline advancements, and financial performance in a competitive biopharmaceutical landscape.

Biogen's 2023 annual report details a year of strategic shifts, including acquisitions, pipeline adjustments, and cost-saving measures, alongside a decline in overall revenue.

Biogen Inc. director William A. Hawkins was granted 1,505 restricted stock units as part of his director compensation.

Biogen Inc. director Stephen A. Sherwin was granted 1,505 restricted stock units as part of his compensation.

Biogen Inc. director Eric K. Rowinsky was granted 1,505 restricted stock units as part of his compensation package.

Biogen Inc. director Jesus B. Mantas acquired 1,505 restricted stock units as part of an equity compensation grant.

Biogen Inc. director Susan Langer was granted 1,505 restricted stock units as part of an equity compensation arrangement.

Biogen Inc. director Monish D. Patolawala was granted 1,505 restricted stock units as part of his director compensation.

Biogen Inc. filed its 2026 Proxy Statement detailing director nominations, executive compensation, and corporate governance practices, with an annual meeting scheduled for June 9, 2026.

Biogen Inc. outlines its multi-year transformation strategy, highlights 2024 achievements including new product launches and cost savings, and details its pay-for-performance executive compensation structure ahead of its June 17, 2025 annual meeting.

Biogen Inc. announces its 2025 Annual Meeting and provides information on how stockholders can access proxy materials and vote.

Biogen's 2025 proxy statement outlines key governance practices, executive compensation aligned with long-term stockholder value, and commitment to corporate responsibility.

Biogen Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 20, 2024, featuring proposals including the election of directors, ratification of the company's accounting firm, executive compensation, and approval of amendments to the company's certificate of incorporation and stock purchase plan.

Biogen is asking stockholders to vote on key proposals including officer exculpation, equity incentive plans, and director elections at its upcoming annual meeting.

Biogen Inc. has finalized its acquisition of Apellis Pharmaceuticals, Inc. through a tender offer and subsequent merger, marking an exit filing for Biogen.

Biogen Inc. announced its definitive agreement to acquire Apellis Pharmaceuticals, Inc. for $41.00 per share in cash plus a contingent value right (CVR) per share, valuing the company at approximately $41 billion.

Biogen Inc. and Biogen MA Inc. have fully divested their 9.941% beneficial ownership in Sage Therapeutics, Inc. by selling all 6,241,473 shares at $8.53 per share.

Biogen Inc. plans to tender its 10% stake in Sage Therapeutics, Inc. following the rejection of its acquisition proposal and Sage's subsequent merger agreement with Supernus Pharmaceuticals, Inc.

Biogen Inc. and its subsidiary Biogen MA Inc. have submitted a non-binding proposal to acquire all outstanding shares of Sage Therapeutics, Inc. not currently owned by them for $7.22 per share in cash.

FMR LLC and Abigail P. Johnson have filed a Schedule 13G reporting beneficial ownership of 11.3% of Biogen Inc. common stock.

FMR LLC, along with Abigail P. Johnson, has filed a Schedule 13G, reporting beneficial ownership of 12,807,541.50 shares of Biogen Inc. common stock, representing 8.7% of the class.

Vanguard Capital Management has disclosed beneficial ownership of 10,989,562 shares, representing 7.48% of Biogen Inc.'s common stock as of March 31, 2026.

The Vanguard Group has reported 0% beneficial ownership in Biogen Inc. common stock following an internal realignment that disaggregated reporting responsibilities.

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 6.4% beneficial ownership stake in Biogen Inc. common stock as of December 31, 2025.

PRIMECAP Management Co. reports an increased beneficial ownership of 10.2% in Biogen Inc., holding nearly 15 million shares.